DNLI - Denali Therapeutics EPS of $1.30 revenue of $294.12M beats by $254.61M
2023-08-08 17:16:49 ET
- Denali Therapeutics press release ( NASDAQ: DNLI ): Q2 EPS of $1.30 may not be comparable to consensus of -$0.63.
- Revenue of $294.12M (+460.4% Y/Y) beats by $254.61M .
For further details see:
Denali Therapeutics EPS of $1.30, revenue of $294.12M beats by $254.61M